News and events archive

Nature Communications publication:A human endothelial cell-based recycling assay for screening of FcRn targeted molecules

The HERA-team. Larger photo and caption under "More"
The HERA-team. Larger photo and caption under "More"

In a study published in Nature Communications on February 12th, establishment of a novel in vitro cellular assay is reported, which can be used to gain in-depth insights into how antibodies and albumin variants are transported in and out of cells, and to predict how efficiently such molecules are rescued from intracellular degradation. The assay has been coined HERA and stands for human endothelial cell-based recycling assay.

The study is based on research conducted by scientists from the Laboratory of Adaptive Immunity and Homeostasis, headed by Jan Terje Andersen, at OUH and UiO, together with several international collaborators from Harvard Medical School, The Jackson Laboratory and Roche Pharma Research and Early Development in Munich.

 

Kyrre Emblem among the three research talents honoured by the Norwegian Research Council

Kyrre Eeg Emblem
Kyrre Eeg Emblem

One of The Norwegian Research Council's three new prizes for young outstanding researchers goes to Kyrre Eeg Emblem from the Department of Diagnostic Physics at the Division of Radiology and Nuclear Medicine. Each prize is 500.000 kroner and will be distributed on March 1st.

Kyrre Eeg Emblem's research will benefit cancer patients directly. Using MRI machines, he can predict how different therapies work on people with cancer. The goal is to understand how the treatment affects the disease, and thereby predict which patients respond to the cancer treatment.

 

Ole Jacob Elle appointed "Innovator of the Month" by "Helse Sør-Øst"

Ole Jacob Elle
Ole Jacob Elle

Ole Jacob Elle, head of the "Medical Robotics, visualisation and navigation" research group at The Intervention Centre at the Divsion of Emergencies and Critical Care has been selected as "Innovator of the Month" by the South-Eastern Norway Regional Health Authority (Helse Sør-Øst RHF). 
Elle's research activities and interests are presented in a popular science article (in Norwegian) entitled "Technology and health - hand in hand". He is fascinated by robots, holograms and navigation systems, and how these things can make everyday life in health care better.

 

Substantial grant from HELSEVEL to Jon Michael Gran

Jon Michael Gran
Jon Michael Gran

Jon Michael Gran, researcher at the Oslo Centre for Biostatistics and Epidemiology (OCBE), recently received a grant of 15 million NOK from the Research Council of Norway (HELSEVEL program). The title of the project is “Effects of workplace initiatives on sick leave and work participation - new statistical and causal models to utilise population registries”. The project will utilise large linked population-wide registry data in assessing the effects of the Norwegian Agreement on a More Inclusive Working Life (the IA Agreement) and the use of graded sick leave on long-term health related absence from work. 

 

Leiv Arne Rosseland "Researcher of the Month" for January 2018

Leiv Arne Rosseland from the Division of Emergencies and Critical Care was appointed "Researcher of the Month" for January 2018 by the South-Eastern Norway Regional Health Authority (Helse Sør-Øst RHF). Rosseland works within the field of pain relief, especially related to obstretic anasthesia. He is also concerned that we use the good registry data that we have more actively than today.
Rosseland's work is presented in a feature article published on the home page of Helse Sør-Øst.

 

Interdepartmental collaboration cuts drug costs on expensive antibodies for treating eye diseases

The Eye-team (larger photo with caption identifying Eye team members under "More")
The Eye-team (larger photo with caption identifying Eye team members under "More")

Since their introduction 12 years ago, intravitreal anti-vascular endothelial growth factor (VEGF) drugs have gradually become the standard of care for several prevalent and debilitating retinal eye diseases. The anti-VEGF treatment is given by an injection into the eye.  In a ground-breaking project, clinicians, researchers and pharmacists at Oslo University Hospital (OUH) and University of Oslo (UiO) have collaborated to improve the safety, efficacy and economy of the anti-VEGF procedure, which in 2017 was performed about 23.000 times at OUH alone. The results are likely to impact practices across Norway and also internationally.

 

Prestigious grant to Tor Erik Rusten

Tor Erik Rusten
Tor Erik Rusten

As one of 24 PIs in Norway (all disciplines included), Tor Erik Rusten, who is group leader at Institute for Cancer Research and PI in Centre for Cancer Cell Reprogramming (CanCell), has been awarded a prestigious “Toppforsk” grant from the Research Council for the project “Tumor-Host Biology”.

Each of the 24 projects receive between 15 and 25 mill NOK. The grants are aimed at research communities that have the potential to become international leaders within their fields.

Two of the 24 selected projects are led by group leaders at the Institute for Cancer Research. The other is Karl-Erik Malmberg from the Department of Cancer Immunology.

 

OUH research seminar, Monday, February 5th, 2018, at 14:30 – 16:00New developments in gynecologic oncology

Welcome to the next Oslo University Hospital (OUH) research seminar entitled:
New developments in gynecologic oncology

Time:  Monday, February 5th, 2018, at 14:30 – 16:00
Place: Red Auditorium, Rikshospitalet, Sognsvannsveien 20, Oslo

Speakers: Annetine Staff, Kjersti Skipar, Ane Gerda Zahl Eriksson, Olesya Solheim and Kristina Lindemann.

 

Karl-Johan Malmberg interviewed by NRK on the potential of killer cell research in cancer treatment

Karl-Johan Malmberg (photo: NRK)
Karl-Johan Malmberg (photo: NRK)

Professor Karl-Johan Malmberg, head of the c at the Department of Cancer Immunology at the Institute for Cancer research, was recently interviewed on radio by the Norwegian Broadcasting Corporation (NRK) in connection with a news item on NRK radio and on their home page about recent research progress on the subject "how killer cells may overcome cancer" (entitled "Drepeceller kan ta knekken på kreft").

 

Therese Sørlie appointed "Scientist of the Month" by "Helse Sør-Øst"

Therese Sørlie
Therese Sørlie

The South-Eastern Norway Regional Health Authority (Helse Sør-Øst) aims to profile ongoing excellent research in the region by calling special attention to a "Scientist of the Month".
This honour recently went to Therese Sørlie, department head at Department of Cancer Genetics at the Institute for Cancer Research and leader of the "Breast tumor initiation and progression" group. She is presented in a feature article (in Norwegian) entitled "Why does cancer become cancer?".

 

Rusten group research project on cell organisation and tumor growth highlighted by the Norwegian Cancer Society

From left: V.H. Lobert, F. O´Farell and T.E. Rusten
From left: V.H. Lobert, F. O´Farell and T.E. Rusten

The Norwegian Cancer Society awarded NOK 173.8 millions NOK to cancer research through the annual open announcement in 2017. They publish popular science articles about research projects supported by them regularly.
The research of Tor Erik Rusten and his coworkers in from the Tumor-Host Biology research group at the Department of Molecular Cell Biology at the Institute for Cancer Research has recently been presented in an article (in Norwegian) entitled "Double agent in the body's cells makes tumors grow". Here it is explained how tumor cells lose orientation and grow uncontrollably when the "double agent" protein LKB1 leads the cells in the wrong direction under certain conditions.

 

Nominating outstanding scientists, closing date March 1st:Excellent Researcher Award and Early Career Award 2018

From the 2017 ceremony. From left: J. Hov, K. Sandvig and T.P. Utheim.
From the 2017 ceremony. From left: J. Hov, K. Sandvig and T.P. Utheim.

Oslo University Hospital announce research awards in the following categories for 2018:

  • Excellent Researcher Award (300.000 NOK)
  • Early Career Award (two prizes of 150.000 NOK)

The candidates must be employed by Oslo University Hospital or University of Oslo, and member of a research group at one of these institutions.

 

OUH research seminar, Monday, January 15th, 2018, at 14:30 – 16:00Genetics of cardiovascular diseases

Welcome to the next Oslo University Hospital (OUH) research seminar entitled:
Genetics of cardiovascular diseases

Time:   Monday, January 15th, 2018, at 14:30 – 16:00
Place: Red Auditorium, Rikshospitalet, Sognsvannsveien 20, Oslo

Speakers: Knut Erik Berge, Kristina Haugaa, Ida Gjervold Lunde, Øyvind H. Lie

 

Press releaseTillotts Pharma AG signs license agreement on antibody technology developed by OUS and UiO scientists

From left: Stian Foss (UiO), Jan Terje Andersen (UiO/OUS), Inger Sandlie (UiO/OUS), Gerbrand Koster (Inven2) and Jørund Sollid (Inven2).
From left: Stian Foss (UiO), Jan Terje Andersen (UiO/OUS), Inger Sandlie (UiO/OUS), Gerbrand Koster (Inven2) and Jørund Sollid (Inven2).

Inven2 AS (Inven2), a technology transfer and innovation company based in Oslo, Norway, and Tillotts Pharma AG (Tillotts), a wholly-owned subsidiary of Zeria Pharmaceutical Co., Ltd. (Zeria) announced on January 22nd that they have signed a license agreement granting Tillotts certain rights to a proprietary antibody backbone technology developed by Stian Foss, Inger Sandlie and Jan Terje Andersen at the University of Oslo and Oslo University Hospital (the Institutions). The partnership is governed by a license agreement, and also includes specific analyses conducted by the Institutions to aid in the lead candidate selection.

 

Cell therapy research presented in national newspaper VG

Research on immunotherapy conducted at the Department of Oncology is presented in a feature article in the popular national Norwegian newspaper Verdens Gang (VG) January 9th. The article focuses on recent progress in chimeric antigen receptor (CAR) T cell therapy. For two years, children with leukemia and adults with lymphoma has been treated through clinical studies. Now the project will be expanded with three new studies on lymphomas.

 

Preclinical drug screening identifies novel stratified treatment options according to the consensus molecular subtypes of colorectal cancer

From left: Anita Sveen, Jarle Bruun and Peter W. Eide.
From left: Anita Sveen, Jarle Bruun and Peter W. Eide.

In two recent publications (Eide PW et al. Sci Rep; Sveen A*, Bruun J* et al. Clin Cancer Res), scientists in the Lothe lab., Department of Molecular Oncology, have identified novel potential treatment strategies for colorectal cancer (CRC), guided by the consensus molecular subtypes (CMS). Combining algorithm development, for translation of CMS classification to preclinical models, with drug screening of classified cell lines and patient-derived xenografts (PDXs) in collaboration with the Finnish Institute for Molecular Medicine and Vall d´Hebron Institute of Oncology, a potential to overcome chemoresistance in the poor prognostic CMS4-mesenchymal group was identified by combination therapy with 5-fluorouracil (5-FU) and HSP90 inhibitors.

 

The discovery of TIGIT as a potential new target for immune checkpoint blockade is published in Clinical Cancer Research.

From left: Kanutte Huse, Sarah Josefsson and June Myklebust
From left: Kanutte Huse, Sarah Josefsson and June Myklebust

Biological advances have resulted in immunotherapeutic regimens that target co-inhibitory receptors such as PD-1 to reverse T-cell exhaustion and promote anti-tumor responses that eradicate human tumors. However, despite its success in many cancer types, a substantial number of patients do not respond to PD-1/PD-L1 blockade. This includes patients with the B-cell malignancy follicular lymphoma, suggesting that co-blockade of co-inhibitory receptors may be necessary to achieve optimal anti-tumor T-cell responses.
In a study recently published in Clinical Cancer Research (journal impact factor 9.6), the authors demonstrate the power of using high dimensional flow cytometry analysis of follicular lymphoma tumors to identify new targets for checkpoint blockade.

 

Scientists from the Research Institute of Internal Medicine receive funding from ERA-Net

From left: Arne Yndestad, Pål Aukrust and Bente Halvorsen
From left: Arne Yndestad, Pål Aukrust and Bente Halvorsen

Professor Pål Aukrust has together with senior scientist dr. Arne Yndestad and professor Bente Halvorsen received ERA-NET funding on cardiovascular diseases (ERA-CVD). All three scientists are affiliated Research Institute of Internal Medicine at the Division of Surgery, Inflammatory Medicine and Transplantation (“KIT”), Oslo University Hospital and Institute of Clinical Medicine, University of Oslo.

The funding, amounting to 2.4 mill NOK over a period of three years, is based on a collaborative project with professor Joachim Schultze, Bonn, Germany, professor Michael Sieweki, Marseille, France, and professor Erik A Biessen, Maastricht, The Netherlands, who is heading the consortium. The project named AtheroMacHete (Atherosclerosis Macrophage Heterogeneity study) will particular focus on intra plaque macrophage heterogeneity in patients with atherosclerotic disorders and experimental model systems.

 

Oslo University Hospital has awarded 6 excellent articles for the first half-year of 2017

Award winners during the ceremony (photo Pål Bakke)
Award winners during the ceremony (photo Pål Bakke)

Six research groups were awarded for their excellent papers published during the first half-year of 2017 during a ceremony on December 16th. Each group received NOK 50.000 for use in further research. The prize winners gave short presentations of the main findings in their respective articles.

The six selected articles are of especially high quality, and they present important finding on both-short and long-term scales. The works reflect the good quality and the interdisciplinarity that characterises several research environments at Oslo University Hospital. The research is a fundamental condition for the institution to maintain and strenghten the quality in the patient treatment.

 

Per Steinar Halvorsen appointed "Innovator of the Month" by Helse Sør-Øst

Per S.Halvorsen(photo: Hedda Holth)
Per S.Halvorsen
(photo: Hedda Holth)

Per Steinar Halvorsen, head of the "Clinical and experimental cardiovascular monitoring" research group at the Intervention Centre at the Division of Emergencies and Clinical Care, was appointed "Innovator of the Month" for the month of October by South-Eastern Norway Regional Health Authority (Helse Sør-Øst).
His work is presented in an article (in Norwegian) entitled "Pacemaker of the future", published on the home page of Helse Sør-Øst.

 
Previous news articles
 The challenges of discovering new antibiotics OUH research seminar, Monday, December 4th 14:30 
 The Laboratory of Adaptive Immunity and Homeostasis enters a strategic research collaboration with a leading pharmaceutical company Press release – 29 Nov 2017 
 Alicia Llorente participates in an ERA-NET funded project  
 Young Investigator Prize to Anita Sveen during annual "Onkologisk Forum" meeting Nov 2017  
 Michael Bretthauer appointed "Scientist of the Month" by "Helse Sør-Øst"  
 Paper on novel pathway selected for inclusion in the ‘In This Issue’ section of Journal of Cell Science  
 Jan Terje Andersen receives a grant of 8.5 million NOK from NANO2021  
 Professor Kjetil Taskén is presented as new director of the Department of Cancer Research at the Cancer Clinic, Oslo University Hospital  
 Pan-cancer analysis of homozygous deletions in primary tumours uncovers rare tumour suppressors Nature Communications publication: 
 A study of the epigenetics of breast cancer provides clues to mechanisms behind subtypes of the disease Nature Communications publication: 
 Maria Torgersen receives a grant of 8.5 million NOK from NANO2021  
 Inequality in genetic cancer risk: Bad genes or bad luck? Nature Communications article from OCBE: 
 Rusten group uncovers new regulatory mechanism of the Peutz-Jeghers cancer syndrome kinase, LKB1 Update: Nature Cell Biology paper attracts interest: 
 Major study of genetics of breast cancer provides clues to mechanisms behind the disease CNN coverage: 
 Albumedix has signed research agreement with OUS and UiO on CIR research  
 CCB researchers uncover novel mechanism of cellular metabolic control  
 New additional treatment for breast cancer patients Breast cancer research highlighted by the Norwegian Cancer Society: 
 Individualized cancer treatment OUH research seminar, Monday, October 9th 14:30 
 Induced pluripotent stem cell research featured on Norwegian national news broadcast  
 Tor Inge Tønnessen "Researcher of the Month" for September  
 Collaboration to identify novel biomarkers that can predict whether a patient will respond positively to pembrolizumab  
 Scientific opportunities in Europe Sept 29th - Information day about EMBL, EMBO and HSPF: 
 Jahre lecture Thursday September 14th  
 The Norwegian Cancer symposium 2017 on Precision Medicine Scandic Holmenkollen Park, December 4-6, 2017: 
 Anne-Lise Børresen-Dale appointed Commander of the Royal Norwegian St. Olavs Order  
 ERC Starting Grant 2017 to Kyrre Eeg Emblem  
 Tone Rustøen "Researcher of the Month" for July  
 Håvard Danielsen appointed "Scientist of the Month" by "Helse Sør-Øst" for June 2017  
 OUH scientists involved in sequencing study of osteosarcoma that has identified mutations in IGF signalling genes  
 Øyvind S. Bruland appointed "Innovator of the Month" by Helse Sør-Øst  
 Lars Tjelta Westlye appointed "Scientist of the Month" by "Helse Sør-Øst" for May 2017  
  Annuncement of research funding from South-East Norway regional health authority for 2018 Call for applications 2018 
 Oslo University Hospital has awarded 6 excellent articles for the second half-year of 2016  
 Clinically important genetic heterogeneity in colorectal cancers with microsatellite instability  
 Per O. Seglen awarded King Olav V's cancer research prize for 2017  
 New mechanism for rare skin disorder discovered  
 Norwegian research with international impact Less expensive medicine results in treatment for more patients 
 The 2017 Excellent Research Awards to Kirsten Sandvig, Johannes Espolin Roksund Hov and Tor Paaske Utheim  
 Organ donation for abdominal and thoracic organs OUH research seminar, Monday, May 8th 14:30 - 16:00 
 Placing my research in an H2020 project Program Info - workshops held May 8-9th: 
 New insight into late effects after cancer treatment presented by the Norwegian Cancer Society  
 Immunotherapy for Cancer OUH research seminar, Tuesday, April 25th 10:00 - 15:45 
 Study on replication fork stability from Skarstad group published in Nucleic Acids Research  
 Innovation to Finance Research OUH research seminar, Monday, April 3rd 14:30 
 NORMENT researchers contribute to PLOS Medicine article on genetic assessment of age-associated Alzheimer's disease risk  
 The AACR-WICR Friend Lectureship presented to Anne-Lise Børresen-Dale  
 CanCell – a new Centre of Excellence – will reprogram cancer cells  
 Jørgen Wesche appointed group leader for the Mesenchymal Cancer Biology Group at the Department of Tumor Biology New group leader at the Institute for Cancer Research: 
 Prestigious research prize from the Norwegian Cancer Society to pioneer in autophagy research King Olav V´s Cancer Research Prize to Per O. Seglen Mar 7, 2017
 Health after transplantation OUH research seminar, Monday, March 6th 14:30 
 Early signs of mental illness in the developing brain NORMENT study published in Nature Neuroscience: 
 Arne Klungland talks about embryo research Breakfast lecture in Oslo Wednesday March 1st: 
 Thon Awards seminars 2017 Invitation to seminar March 2nd 12:00 
 Critical article on doping and drug testing published in EMBO reports  
 Early phase drug development: From idea to concept OUH research seminar, Monday, February 6th 14:30 
 "Science" article from Johanna Olweus's group highlighted by editorial in New England Journal of Medicine  
 6th National Conference on Stroke Oslo Kongressenter, February 09-10 2017 
 Theis Tønnessen appointed "Scientist of the Month" by "Helse Sør-Øst" for January 2017  
 Sepsis: New definitions and future research OUH research seminar, Thursday, January 26th 
 Excellent Researcher Award and Early Career Award 2017 Announcement: Nominating outstanding scientists, closing date March 1st: 
 Antimicrobial resistance - how bad is the situation in the world of virus, fungus and mycoplasma? OUH research seminar, Monday, January 16th 
 Findings from Rusten group published in Nature on microenvironmental autophagy draw nationwide attention Updated: honoured with "Preview" article in Developmental Cell  
 Commentary article from Arne Klungland in Nature Methods on epitranscriptome analysis  
 Research funding from South-Eastern Norway Regional Health Authority for 2017  
 Educating future cancer researchers from Ullern high school  
 Novel cancer immunotherapy published in Cancer Research, with cover illustration  
 Oslo University Hospital has awarded 6 excellent articles for the first half-year of 2016  
 Oslo University Hospital research seminar: Exercise and Brain Energy Monday, November 21st, 2016, at 14:30 – 16:10 
 Oslo University Hospital research seminar: The World of Immunology Thursday November 17th at 10:00-15:00 
 Oslo University Hospital researchers receive 77.3 mill NOK from the Norwegian Cancer Society Results of Open Call 2016: 
 Human lung macrophages are self-maintained for several years  
 Announcement of research funding from the Norwegian Cancer Society Gathering Friday October 28th 10-12 at UiO: 
 Dag Berild awarded the "Akademikerprisen" for his work on antibiotic resistance  
 50 years anniversary Institute for Surgical Research Thursday 13 October 2016 at 10.15 AM 
 Making therapeutic antibodies from scratch  
 Lina Prasmickaite's work presented in popularised form  
 Medical imaging in cardiac research Oslo University Hospital research seminar Monday October 10th 
 Focus on personalized medicine and the MetAction study  
 Histone marks regulate maternal-to-zygotic transition Paper from Dahl/Klungland published in the Sep 22nd issue of Nature 
 Turning the tide of antimicrobial resistance National kick-off, Tuesday September 13th 
 Marina Vietri interviewed for major Italian research web portal  
 OUH researchers publish groundbreaking computer tools for cell biology research in Nature Methods  
 POLE proofreading domain mutations identify a subset of immunogenic colorectal cancers with excellent prognosis  
 Clinical Cancer Research highlights biomarker paper from Lyng’s group  
 The Norwegian Cancer Genomics Consortium participates in international study of gene variants predisposing for cancer development.  
 Annuncement of research funding from South-East Norway regional health authority for 2017 Call for applications 2017 
 H.M. the King's Gold Medal to Marina Vietri  
 Oslo University Hospital has awarded 6 excellent articles for the second half-year of 2015  
 Atle Bjørnerud "Innovator of the Month" South-Eastern Norway Regional Health Authority brings attention to innovation: 
 Tomas Lindahl, Nobel Prize laureate 2015 Symposium at OUS, Rikshospitalet, 17. June 2016 13:00-15:30 
 The 2016 Excellent Research Awards to Pål Aukrust, Therese Seierstad and Espen Melum Oslo University Hospital honouring outstanding scientific work: 
 Strønen and Olweus publish article in Science on the use of donor immunity to target cancer  
 Håvard Danielsen and Erik Fosse receive Lighthouse project grants from the Norwegian Research Council  
 "Intelligent needle tracking using ultrasound imaging for improved minimally invasive interventions" supported by EU OUS scientists partners in project funded by HORIZON 2020 FAST TRACK TO INNOVATION 
 Discovery of biologically active small molecular compounds Oslo University Hospital research seminar Monday May 9th 
 Mapping somatic mutations in breast cancer whole genomes OUS scientists co-author Nature article: 
 Same, but different? Genetic analysis of five immune mediated diseases reveals molecular taxonomy of chronic inflammation  
 Immunotherapy for Cancer Day of Immunology Conference 2016 April 29 
 New guidelines for "Helse Sør-Øst" and "Kreftforeningen" applications Information meeting, Radiumhospitalet, Friday April 22nd 
 Ståle Nygård – Dept. of Core Facilities Institute seminar April 6th 
Page visits: 2164